tetano
Editor, Senior Moderator
Reumatol Clin
. 2020 Jun 17;S1699-258X(20)30142-X.
doi: 10.1016/j.reuma.2020.06.003. Online ahead of print.
Anakinra as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated With SARS-CoV-2 Refractory to Tocilizumab
[Article in English, Spanish]
Luis Figuero-P?rez[SUP] 1 [/SUP], Alejandro Olivares-Hern?ndez[SUP] 2 [/SUP], Roberto A Escala-Cornejo[SUP] 3 [/SUP], Eduardo Ter?n-Brage[SUP] 2 [/SUP], ?lvaro L?pez-Guti?rrez[SUP] 2 [/SUP], Juan J Cruz-Hern?ndez[SUP] 2 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
Keywords: Anakinra; Cytokine storm; SARS-CoV-2; Tocilizumab; Tormenta de citocinas.
. 2020 Jun 17;S1699-258X(20)30142-X.
doi: 10.1016/j.reuma.2020.06.003. Online ahead of print.
Anakinra as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated With SARS-CoV-2 Refractory to Tocilizumab
[Article in English, Spanish]
Luis Figuero-P?rez[SUP] 1 [/SUP], Alejandro Olivares-Hern?ndez[SUP] 2 [/SUP], Roberto A Escala-Cornejo[SUP] 3 [/SUP], Eduardo Ter?n-Brage[SUP] 2 [/SUP], ?lvaro L?pez-Guti?rrez[SUP] 2 [/SUP], Juan J Cruz-Hern?ndez[SUP] 2 [/SUP]
Affiliations
- PMID: 32571730
- DOI: 10.1016/j.reuma.2020.06.003
Abstract
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
Keywords: Anakinra; Cytokine storm; SARS-CoV-2; Tocilizumab; Tormenta de citocinas.